ArticleCurrent medical imaging2025
Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging for Assessing Liver Function in Primary Biliary Cholangitis
Article in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gd-EOB-DTPA-enhanced MRI in the diagnosis of intrahepatic cholestasis in mice: an experimental study.BMC medical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to detect the performance of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) for assessing primary biliary cholangitis (PBC).
methodsSeventy-five patients with PBC were included in this prospective study. Shear wave elastography (SWE) and Gd-EOB-DTPA-enhanced MRI were conducted, and then the signal intensity ratio (SIR) and contrast enhancement index (CEI) in different phases, including portal venous phase (PVP), equilibrium phase (EP), and hepatobiliary phase (HBP), were calculated. Afterward, the results were compared with Child-Pugh grading and non-invasive liver fibrosis models using the Kruskal-Wallis H test or Chi-squared test. The area under the curve (AUC) was applied to evaluate the diagnostic performance of SIRHBP, CEIHBP, and SWE across different Child-Pugh grades.
resultsSWE (p<0.001), SIRHBP (p<0.001), CEIHBP (p<0.001), APRI (p=0.002), and FIB-4(p<0.001) showed significant differences in different Child-Pugh grades. Statistically significant differences were found in SIRHBP (p=0.005), CEIHBP (p=0.010), and FIB-4 (p=0.001) of different SWE levels. For the diagnosis of Child-Pugh C, the AUC of SWE, SIRHBP, and CEIHBP were 0.889, 0.778, and 0.761, respectively. Correspondingly, the sensitivity was 75.0%, 64.4%, and 54.2%, and the specificity was 94.9%, 100%, and 100%, respectively. For the diagnosis of Child-Pugh B+C, the AUC of SWE, SIRHBP, and CEIHBP were 0.919, 0.809, and 0.814, respectively. DISCUSSION: Our study confirmed that Gd-EOB-DTPA-enhanced MRI is an effective and objective method for assessing liver function in patients with PBC.
conclusionSIRHBP and CEIHBP could be regarded as a novel imaging biomarker to evaluate liver function. Gd-EOB-DTPA-enhanced MRI and SWE outperformed serum-based models in sensitivity and specificity, strengthening the value of imaging in clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.